Literature DB >> 10417149

Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.

M M Rodrigues1, M Ribeirão, V Pereira-Chioccola, L Renia, F Costa.   

Abstract

Immunization with a plasmid DNA containing the gene encoding the catalytic domain of trans-sialidase (TS) elicits protective immune responses against experimental Trypanosoma cruzi infection. As several studies provided strong evidence that during infection CD4 Th1 and CD8 T cytotoxic type 1 (Tc1) cells are important factors in host resistance, the present study was designed to evaluate which T-cell types were activated in DNA-vaccinated BALB/c mice. We found that bulk cells from DNA-immunized mice had CD4 and CD8 T cells that produced gamma interferon (IFN-gamma) but not interleukin-4 (IL-4) or IL-10. To characterize the TS-specific T cells at the clonal level, we generated CD4 and CD8 clones. We obtained cytotoxic CD4 clones of the Th1 type that secreted large amounts of IFN-gamma but not IL-4 or IL-10. Unexpectedly, we obtained other CD4 clones with a Th2 phenotype, secreting IL-4 and IL-10 but not IFN-gamma. All CD8 clones were cytotoxic and produced IFN-gamma. IL-4 and IL-10 were not secreted by these cells. Using synthetic peptides, we determined a CD8 epitope recognized by several clones as being represented by amino acids IYNVGQVSI. The antiparasitic activity of a CD4 Th1 and a CD8 Tc1 clone was assessed in vitro. CD4 or CD8 T cells significantly inhibited T. cruzi development in infected macrophages or fibroblasts, respectively. We concluded that DNA vaccine efficiently generates potentially protective CD4 Th1 and CD8 Tc1 cells specific for a T. cruzi antigen, therefore reinforcing the possibility of using this strategy for developing a preventive or therapeutic vaccine against Chagas' disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417149      PMCID: PMC96665     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

1.  Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.

Authors:  B Wizel; N Garg; R L Tarleton
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

Review 2.  DNA vaccines.

Authors:  J B Ulmer; J C Sadoff; M A Liu
Journal:  Curr Opin Immunol       Date:  1996-08       Impact factor: 7.486

3.  CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.

Authors:  H L Davis; R Weeratna; T J Waldschmidt; L Tygrett; J Schorr; A M Krieg; R Weeranta
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

4.  Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes.

Authors:  Y H Chow; B L Chiang; Y L Lee; W K Chi; W C Lin; Y T Chen; M H Tao
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

Review 5.  The instructive role of innate immunity in the acquired immune response.

Authors:  D T Fearon; R M Locksley
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

6.  A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells.

Authors:  S Schenkman; M S Jiang; G W Hart; V Nussenzweig
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

7.  Trypanosoma cruzi infection in MHC-deficient mice: further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease.

Authors:  R L Tarleton; M J Grusby; M Postan; L H Glimcher
Journal:  Int Immunol       Date:  1996-01       Impact factor: 4.823

8.  Immunostimulatory DNA sequences necessary for effective intradermal gene immunization.

Authors:  Y Sato; M Roman; H Tighe; D Lee; M Corr; M D Nguyen; G J Silverman; M Lotz; D A Carson; E Raz
Journal:  Science       Date:  1996-07-19       Impact factor: 47.728

9.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.

Authors:  A L de Andrade; F Zicker; R M de Oliveira; S Almeida Silva; A Luquetti; L R Travassos; I C Almeida; S S de Andrade; J G de Andrade; C M Martelli
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

10.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up.

Authors:  R Viotti; C Vigliano; H Armenti; E Segura
Journal:  Am Heart J       Date:  1994-01       Impact factor: 4.749

View more
  21 in total

1.  Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.

Authors:  Vera Lucia Pereira-Chioccola; Abilio Augusto Fragata-Filho; Antonio Marcos de Apparecida Levy; Mauricio M Rodrigues; Sergio Schenkman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

2.  Distinct kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice.

Authors:  Fanny Tzelepis; Bruna C G de Alencar; Marcus L O Penido; Ricardo T Gazzinelli; Pedro M Persechini; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

3.  Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection.

Authors:  Silvia B Boscardin; Sheila S Kinoshita; Adriana E Fujimura; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

4.  DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene.

Authors:  A E Fujimura; S S Kinoshita; V L Pereira-Chioccola; M M Rodrigues
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

5.  Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice.

Authors:  Eric Dumonteil; Javier Escobedo-Ortegon; Norma Reyes-Rodriguez; Arletty Arjona-Torres; Maria Jesus Ramirez-Sierra
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.

Authors:  Nisha Garg; Rick L Tarleton
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

7.  Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.

Authors:  Eduardo L V Silveira; Carla Claser; Filipe A B Haolla; Luiz G Zanella; Mauricio M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

8.  NK-lysin and its shortened analog NK-2 exhibit potent activities against Trypanosoma cruzi.

Authors:  Thomas Jacobs; Heike Bruhn; Iris Gaworski; Bernhard Fleischer; Matthias Leippe
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.

Authors:  G Salay; M L Dorta; N M Santos; R A Mortara; C Brodskyn; C I Oliveira; C L Barbiéri; M M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2007-07-11

10.  Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy.

Authors:  Masaharu Katae; Yasushi Miyahira; Kazuyoshi Takeda; Hironori Matsuda; Hideo Yagita; Ko Okumura; Tsutomu Takeuchi; Tsuneo Kamiyama; Akihiko Ohwada; Yoshinosuke Fukuchi; Takashi Aoki
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.